Patents Examined by Robert A. Wax
  • Patent number: 11364199
    Abstract: An oil-in-water nanoemulsion is provided. The nanoemulsion contains 8-12% w/v essential oil, 1-5% w/v polysorbate 80 surfactant, 2-6% w/v glyceryl citrate/lactate/linoleate/oleate co-surfactant, and 1-5% w/v glycerol monocaprylate, type I, wherein a ratio of the surfactant and co-surfactant to essential oil is from 1:1.1 to 1:1.6. Methods of preparing the nanoemulsion and for the transdermal delivery of the nanoemulsion are also provided.
    Type: Grant
    Filed: November 9, 2021
    Date of Patent: June 21, 2022
    Assignee: KING ABDULAZIZ UNIVERSITY
    Inventors: Hossam H. Tayeb, Raed Felimban, Nojod Hasaballah, Jwana Bin Mahfouz, Adeel Chaudhary, Majed Felemban, Fuad Alnadwi, Waleed Rizg
  • Patent number: 11364183
    Abstract: The present invention relates to a cosmetic system comprising an applicator and a gel composition, and methods for making-up and enhancing the appearance of keratinous materials using the systems.
    Type: Grant
    Filed: April 30, 2018
    Date of Patent: June 21, 2022
    Assignee: L'ORÉAL
    Inventors: Geoffrey David White, Lemis Noya Tarajano
  • Patent number: 11364227
    Abstract: The disclosure is directed to ABC294640, as free base or as salts thereof, in preparing medicines for treating coronavirus infection or preventing diseases caused by coronavirus infection, and a medicine for preventing coronavirus infection or preventing diseases caused by coronavirus infection.
    Type: Grant
    Filed: October 15, 2021
    Date of Patent: June 21, 2022
    Assignee: RedHill Biopharma Ltd.
    Inventors: Dror Ben-Asher, Reza Fathi
  • Patent number: 11357888
    Abstract: Disclosed is a nano-layered dual hydroxide-biological factor combined system for promoting nerve regeneration to repair a spinal cord injury. The preparation method therefor comprises: 1) synthesizing a nano-layered dual hydroxide CL1; and 2) co-incubating 10 mg CL1 and 200-2000 ng of biological factors NT3, VEGF or bFGF in a low-speed shaker at 4° C. for 2 hours using an ion exchange method, centrifuging same and then obtaining the precipitate. Experiments on transection and resorption spinal cord injury models show that this combined system has a significant recovery effect on the behavior of model mice, can reconstruct the neural circuit of a damaged area over time and achieves an ideal repair effect with regard to a spinal cord injury.
    Type: Grant
    Filed: October 23, 2018
    Date of Patent: June 14, 2022
    Assignee: Shanghai Tongji Hospital
    Inventors: Liming Cheng, Shilong Wang, Rongrong Zhu
  • Patent number: 11357732
    Abstract: A two-compartment capsule includes a body, a diaphragm between which seals off the body and provides a first compartment to hold a first ingredient, and a cap applied to the body whereby a space between the inner portion of the cap and the diaphragm defines a second compartment for holding a second ingredient. This disclosure also provides certain ranges for the volumes of the first compartment and the second compartment, as well as a volume ratio of the first compartment to the second compartment, lengths of the first and second compartments, and the length of contact between a sidewall of the diaphragm and a sidewall of the body. Furthermore, particular ingredients and formulations for the two-compartment capsule where volume is critical for a therapeutic effect are disclosed.
    Type: Grant
    Filed: October 10, 2016
    Date of Patent: June 14, 2022
    Assignee: ComboCap, Inc.
    Inventor: Tobias Johan Louw
  • Patent number: 11344526
    Abstract: Provided herein are drug implants comprising a therapeutically active agent for the treatment of disease in a subject. In some cases, the drug implant may comprise a polymer matrix and a therapeutically active agent disposed therein. Additionally provided are methods for manufacturing the drug implants and methods of treating diseases with the implants. In some cases, the drug implant may comprise bicalutamide, e.g., for use in the treatment of prostate cancer.
    Type: Grant
    Filed: March 20, 2020
    Date of Patent: May 31, 2022
    Assignees: The Regents of the University of California, Alessa Therapeutics, Inc.
    Inventors: Maithili Rairkar, Pujan Desai, Carlos Schuler, Maxime Daud, Maxime D. Rappaport, Pamela Munster, John Maroney, Margaret McLaughlin, Tobias H. Casab, Keith Hall, Scott Thomas
  • Patent number: 11344653
    Abstract: Provided is a bone fixation material that does not deteriorate in properties even by an electron beam sterilization treatment performed before or during use as a bone fixation material, has fatigue resistance, wear resistance, and dimensional stability at excellent levels, also has biocompatibility, and offers excellent osteoconnectivity. The bone fixation material according to the present invention includes a nonwoven fabric made of PEEK fibers. The bone fixation material according to the present invention preferably has an average pore size of 3 to 280 ?m and preferably has a porosity of 15% to 70%. The PEEK fibers preferably have an average fiber diameter of 10 ?m or less.
    Type: Grant
    Filed: December 22, 2017
    Date of Patent: May 31, 2022
    Assignee: DAICEL CORPORATION
    Inventors: Takashi Arai, Yo Yamato, Koji Nakane, Naoki Shimada, Hanako Asai
  • Patent number: 11337906
    Abstract: The present disclosure relates to hair care and conditioning compositions; and to methods for conditioning, managing, and/or styling the hair using the compositions. The hair conditioning and managing compositions are substantially anhydrous and include: propylene glycol; one or more monoalcohols having from 2 to 6 carbon atoms; one or more cationic surfactants; and one or more fatty compounds. The compositions are solubilized, non-emulsified compositions until applied to wet or damp hair, whereupon the compositions form a lamellar phase in situ.
    Type: Grant
    Filed: December 31, 2019
    Date of Patent: May 24, 2022
    Assignee: L'OREAL
    Inventors: Heather Lee, Dongcui Li, Jun Liang
  • Patent number: 11337989
    Abstract: The present disclosure relates to compositions and methods for inhibiting inflammation and reducing the risk of spreading sexually transmitted diseases using an alginic acid-based antimicrobial compound. Such compositions provide dual protection by (1) attacking and inactivating viruses and other microbes and (2) blocking the host response that viruses trigger to invade host cells. Such compositions can also be part of an acid buffering contraceptive.
    Type: Grant
    Filed: December 19, 2014
    Date of Patent: May 24, 2022
    Assignee: Evofem, Inc.
    Inventors: Wendell Guthrie, Gary S. Hahn
  • Patent number: 11338119
    Abstract: Provided herein are drug implants comprising a therapeutically active agent for the treatment of disease in a subject. In some cases, the drug implant may comprise a polymer matrix and a therapeutically active agent disposed therein. Additionally provided are methods for manufacturing the drug implants and methods of treating diseases with the implants. In some cases, the drug implant may comprise bicalutamide, e.g., for use in the treatment of prostate cancer.
    Type: Grant
    Filed: March 20, 2020
    Date of Patent: May 24, 2022
    Assignees: The Regents of the University of California, Alessa Therapeutics, Inc.
    Inventors: Maithili Rairkar, Pujan Desai, Carlos Schuler, Maxime Daud, Maxime D. Rappaport, Pamela Munster, John Maroney, Margaret McLaughlin, Tobias H. Casab, Keith Hall, Scott Thomas
  • Patent number: 11331315
    Abstract: The present invention is directed to an aripiprazole oral soluble film and a preparation method thereof. The aripiprazole oral soluble film comprises 10-60% w/w of aripiprazole in a crystalline state and 30-95% w/w of one or more film-forming materials, wherein 90% of the aripiprazole particles have a size of ?14.3 ?m and are uniformly blended in the film without visible undispersed particles. The aripiprazole oral soluble film has excellent bioavailability, uniformity, stability, and palatability. The oral soluble film preparation is prepared by first grinding aripiprazole particles to have desired small particle sizes, then blending the aripiprazole particles with film forming materials in an aqueous solution to a uniform suspension, defoaming the suspension, and coating the suspension on a substrate and drying it to form a film.
    Type: Grant
    Filed: November 3, 2020
    Date of Patent: May 17, 2022
    Assignee: XIAMEN LP PHARMACEUTICAL CO., LTD.
    Inventors: Rongbin Ling, Lingyu Cai, Fuxiang Lin, Yong Yu, Xiaojin Xiao
  • Patent number: 11334695
    Abstract: The present invention relates to personal care compositions comprising malodor reduction compositions and methods of making and using such personal care compositions. Such personal care compositions comprising the malodor control technologies disclosed herein provide malodor control without leaving an undesireable scent and when perfume is used to scent such compositions, such scent is not unduely altered by the malodor control technology.
    Type: Grant
    Filed: September 19, 2017
    Date of Patent: May 17, 2022
    Assignee: The Procter & Gamble Company
    Inventors: Jonathan Robert Cetti, Gayle Marie Frankenbach, Steven Anthony Horenziak, Judith Ann Hollingshead
  • Patent number: 11334694
    Abstract: The present invention relates to personal care compositions comprising malodor reduction compositions and methods of making and using such personal care compositions. Such personal care compositions comprising the malodor control technologies disclosed herein provide malodor control without leaving an undesirable scent and when perfume is used to scent such compositions, such scent is not unduly altered by the malodor control technology.
    Type: Grant
    Filed: September 25, 2015
    Date of Patent: May 17, 2022
    Assignee: The Procter & Gamble Company
    Inventors: Jonathan Robert Cetti, Gayle Marie Frankenbach, Steven Anthony Horenziak, Judith Ann Hollingshead
  • Patent number: 11331266
    Abstract: The application provides pharmaceutical compositions comprising stable concentrated solutions of antioxidant free norepinephrine bitartrate for injection dispensed in glass containers and methods of providing such solutions to a subject.
    Type: Grant
    Filed: October 29, 2020
    Date of Patent: May 17, 2022
    Assignee: Medefil, Inc.
    Inventors: Pradeep Aggarwal, Lincoln W. Maina, Sunil Potdar, Ravinder Malhotra, Venugopal Chenna, Sandeep Pallerla, NagaBhuvan Kumar Nandipati
  • Patent number: 11331392
    Abstract: The invention provides for novel thermo-responsive polymers and compositions comprising the same. In some embodiments, the polymers are water soluble, pH-degradable and have tunable lower critical solution temperatures. Other aspects of the invention include micelles and gels comprising the thermo-responsive polymers and derivatives thereof, as well as methods of delivering therapeutic agents comprising administering a biodegradable gel or micelle comprising a polyacetal compound cross-linked with a linker.
    Type: Grant
    Filed: December 3, 2015
    Date of Patent: May 17, 2022
    Assignee: The Trustees of Columbia University in the City of New York
    Inventors: Jeffrey T. Koberstein, Sanjoy Samanta, Chathuranga De Silva
  • Patent number: 11324774
    Abstract: Compositions of alkaline salts and metabolic acid inducers and methods of use thereof are provided. The disclosed compositions may be used for stimulating vagal nerve efferent pathways, treating or preventing an inflammatory response or an autoimmune disorder, inhibiting or reducing one or more inflammatory M1 macrophages and/or one or more inflammatory neutrophils in the blood, promoting polarization of macrophages from a pro-inflammatory M1 state to an anti-inflammatory M2 state, and treating or preventing cardiovascular disease or metabolic disorders.
    Type: Grant
    Filed: January 2, 2019
    Date of Patent: May 10, 2022
    Assignee: Augusta University Research Institute, Inc.
    Inventors: Paul O'Connor, Ryan Harris
  • Patent number: 11324721
    Abstract: Embodiments are directed to secnidazole formulations and the use of a secnidazole formulation for the treatment of trichomoniasis in a subject in need thereof.
    Type: Grant
    Filed: June 2, 2020
    Date of Patent: May 10, 2022
    Assignee: Lupin Inc.
    Inventors: Helen S. Pentikis, David Palling, Carol J. Braun
  • Patent number: 11324673
    Abstract: The present invention is directed to targeted delivery of a cold slurry underneath a patient's skin to improve the cosmetic appearance of the skin. The “target” tissue can be muscle tissue that when cooled cannot contract and cause wrinkles/lines in the skin to appear. The target tissue can also be adipose tissue that causes overlying tissue to sag and form wrinkles/lines. The cold slurry induces apoptosis, and reduces the size of the tissue, and causes the connective tissue supporting the skin to thicken and tighten, thereby reducing wrinkles/lines. Skin can also be tightened with cold slurry injected into the dermis layer of the skin or within the layers of the oral mucosa making a cold slurry treatment ideal for reducing the appearance of baggy skin after a patient loses weight and or for treating obstructive sleep apnea. Cold slurry can also be used to treat cellulite and acne.
    Type: Grant
    Filed: August 21, 2017
    Date of Patent: May 10, 2022
    Assignee: MIRAKI INNOVATION THINK TANK LLC
    Inventors: Christopher Velis, Karen Miller
  • Patent number: 11324767
    Abstract: Provided herein is a novel method for creating fixed, non-antagonistic molar ratios of drugs in and around the bone environment for desired periods of time. This method enables treating bone and bone-related disease by administering a pharmaceutical composition comprising a bone-targeted therapeutic agent able to release a drug payload from the bone surface, in addition to a second therapeutic agent. Such methods are useful in the treatment of bone and bone-related diseases, such as cancer-induced bone disease, osteomyelitis and bone infection, bone pain and inflammatory bone disease, metabolic disease, as well as others.
    Type: Grant
    Filed: January 5, 2018
    Date of Patent: May 10, 2022
    Assignee: MBC PHARMA, INC.
    Inventors: Shawn Zinnen, Alexander Karpeisky
  • Patent number: 11324852
    Abstract: The present invention relates to coated silk films. Further, the present invention relates to pharmaceutical or cosmetic compositions comprising the coated silk films. Furthermore, the present invention relates to coated silk films or pharmaceutical compositions comprising the coated silk films for use in medicine. In addition, the present invention relates to methods of producing the coated silk films.
    Type: Grant
    Filed: January 29, 2015
    Date of Patent: May 10, 2022
    Assignee: Amsilk GmbH
    Inventors: Gerhard Winter, Elisa Agostini, Julia Engert, Lin Romer, Ute Slotta